J&J Topamax Expansion Will Include Lennox-Gastaut; "Approvable" At FDA

Johnson & Johnson's first step in expanding the Topamax label within the seizure market could be for a Lennox-Gastaut syndrome indication, Group Chairman Joseph Scodari suggested during an analyst R&D day in La Jolla, Calif. May 30.